Research programme: antibacterials - Ohio State University/Oscient
Alternative Names: Antibacterials research programme - Ohio State University/OscientLatest Information Update: 24 Nov 2004
At a glance
- Originator Ohio State University Research Foundation
- Developer Oscient Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 22 Nov 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 16 Oct 2002 This programme is still in active development